The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 799 Mounjaro articles
This comprehensive update delves into groundbreaking research on GLP-1 receptor agonists and their impact on liver health, alongside crucial developments in inflammatory bowel disease (IBD) management and innovative approaches to digestive symptom relief. Discover how cutting-edge science is shaping patient care and explore practical implications for managing chronic conditions.
New Zealand's Pharmac funding agency has moved semaglutide (Wegovy) to its investment list. Here is what this means for eligibility, costs, and access.
Dive into the captivating world of gourmand fragrances, exploring their resurgence in popularity and a fascinating, unexpected connection to GLP-1 medications. Learn how these sweet scents offer a unique form of sensory indulgence.
Insulin resistance is a critical metabolic condition affecting blood sugar regulation and potentially impacting brain function. This comprehensive guide delves into its causes, symptoms, and the vital role of lifestyle interventions.
Bank of America cuts Hims & Hers price target as the telehealth giant pivots from compounded GLP-1s to branded alternatives. Here is what this shift means for patients.
A groundbreaking study reveals that switching to an oral GLP-1 medication like orforglipron can help individuals maintain a significant portion of their weight loss achieved with injectable therapies, offering a new avenue for long-term obesity management.
Eli Lilly celebrates 150 years with a focus on AI-driven manufacturing, new GLP-1 oral therapies, and expanded neuroscience research, signaling a major shift in pharmaceutical innovation.
A comprehensive analysis of the STEP trials reveals that once-weekly semaglutide significantly benefits older adults with obesity, leading to substantial weight loss and improvements in key cardiometabolic markers. This article delves into the findings, implications, and considerations for this important demographic.
The global GLP-1 meal replacement market is experiencing explosive growth, projected to reach USD 10.9 billion by 2036. This surge is directly linked to the increasing adoption of GLP-1 medications like semaglutide and tirzepatide, alongside a growing consumer preference for convenient, nutrient-dense, and high-protein nutrition solutions designed to support weight management and reduced-appetite lifestyles.
